Vtp-1000
Celiac Disease
Barinthus BiotherapeuticsEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 89/ 100
Competitive context
15 Active assets in the Celiac Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Necator Americanus James Cook University, Queensland, Australia | Phase 2 | BB |
Larazotide 9 Meters Biopharma, Inc. | Phase 3 | BB |
Prolyl Endopeptidase Dr. C. Bonorino Udaondo Gastroenterology Hospital | Phase 4 | BB |
Latiglutenase Entero Therapeutics | Phase 2 | BB |
MACROGOLS Sheffield Teaching Hospitals NHS Foundation Trust | Phase 4 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →